Jurata Thin Film
Developer of thermostable formulation technologies for vaccines, biologics, gene therapies and other APIs. The company formulates active materials into thin-film and liquid presentations that preserve three-dimensional structure and biological activity at ambient and elevated temperatures, enabling reduced cold-chain requirements and alternative, needle-free administration routes.
Industries
Nr. of Employees
small (1-50)
Jurata Thin Film
870 Martin Luther King Jr. Boulevard Chapel Hill, North Carolina 27514
Products
Thermostable thin-film formulation platform
A platform approach that formulates biological materials into a thin, lightweight film that preserves activity at ambient and elevated temperatures and can be administered sublingually, buccally, orally or reconstituted for injection.
Thermostable thin-film formulation platform
A platform approach that formulates biological materials into a thin, lightweight film that preserves activity at ambient and elevated temperatures and can be administered sublingually, buccally, orally or reconstituted for injection.
Services
Collaborative development of thermostable film and liquid presentations tailored to a partner's API, administration route and supply-chain requirements.
Biophysical product characterization, batch release testing, stability studies and potency assays to support development and regulatory submissions.
Optimization of composition and process for thermostable presentations and execution support for preclinical studies assessing stability and delivery performance.
Collaborative development of thermostable film and liquid presentations tailored to a partner's API, administration route and supply-chain requirements.
Biophysical product characterization, batch release testing, stability studies and potency assays to support development and regulatory submissions.
Optimization of composition and process for thermostable presentations and execution support for preclinical studies assessing stability and delivery performance.
Expertise Areas
- Thermostable formulation development
- Vaccine delivery platforms
- Formulation R&D for biologics and gene therapies
- Stability testing and analytical development
Key Technologies
- Thermostable thin-film stabilization
- Liquid biologic formulation
- mRNA-LNP stabilization
- Viral-vector (adenoviral) stabilization
News & Updates
Partnership and funding to support formulation of mRNA-LNP materials into thermostable under-the-tongue film presentations and preclinical evaluation for sublingual delivery.
Award supporting development of a thermostabilized next-generation SARS-CoV-2 vaccine that can be transported and stored without temperature control and delivered without needles.
Selection to participate in a joint initiative with a commercial innovation program and BARDA to advance thermostable thin-film technologies for vaccine preparedness.
Film formulation reconstituted and delivered intranasally conferred 100% survival in non-human primates challenged with lethal Ebola, with films stored at room temperature for 30 days prior to shipping.
Adenoviral vectors reported to remain stable in film for at least three years at room temperature; rehydrated films reported stable for at least eight months.
Partnership and funding to support formulation of mRNA-LNP materials into thermostable under-the-tongue film presentations and preclinical evaluation for sublingual delivery.
Award supporting development of a thermostabilized next-generation SARS-CoV-2 vaccine that can be transported and stored without temperature control and delivered without needles.
Selection to participate in a joint initiative with a commercial innovation program and BARDA to advance thermostable thin-film technologies for vaccine preparedness.
Film formulation reconstituted and delivered intranasally conferred 100% survival in non-human primates challenged with lethal Ebola, with films stored at room temperature for 30 days prior to shipping.
Adenoviral vectors reported to remain stable in film for at least three years at room temperature; rehydrated films reported stable for at least eight months.